<VariationArchive VariationID="1066527" VariationName="NM_000090.4(COL3A1):c.952-2del" VariationType="Deletion" Accession="VCV001066527" Version="7" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-02" DateCreated="2021-05-10" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1055162" VariationID="1066527">
      <GeneList>
        <Gene Symbol="COL3A1" FullName="collagen type III alpha 1 chain" GeneID="1281" HGNC_ID="HGNC:2201" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q32.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="188974373" stop="189012746" display_start="188974373" display_stop="189012746" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791764.1" start="79333" stop="117706" display_start="79333" display_stop="117706" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189839098" stop="189877471" display_start="189839098" display_stop="189877471" Strand="+" />
          </Location>
          <OMIM>120180</OMIM>
          <Haploinsufficiency last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000090.4(COL3A1):c.952-2del</Name>
      <CanonicalSPDI>NC_000002.12:188992181:A:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2q32.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="188992182" stop="188992182" display_start="188992182" display_stop="188992182" variantLength="1" positionVCF="188992181" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189856908" stop="189856908" display_start="189856908" display_stop="189856908" variantLength="1" positionVCF="189856907" referenceAlleleVCF="TA" alternateAlleleVCF="T" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.189856908del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.189856908del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.188992182del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.188992182del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007404.1" sequenceAccession="NG_007404" sequenceVersion="1" change="g.22810del">
            <Expression>NG_007404.1:g.22810del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000090.4" sequenceAccession="NM_000090" sequenceVersion="4" change="c.952-2del" MANESelect="true">
            <Expression>NM_000090.4:c.952-2del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001574" Type="splice acceptor variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_3" sequenceAccession="LRG_3">
            <Expression>LRG_3:g.22810del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2153502163" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000090.4(COL3A1):c.952-2del AND Ehlers-Danlos syndrome, type 4" Accession="RCV001377545" Version="6">
        <ClassifiedConditionList TraitSetID="6334">
          <ClassifiedCondition DB="MedGen" ID="C0268338">Ehlers-Danlos syndrome, type 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-11" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24922459</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-25">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="6334" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1585" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome vascular type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, ecchymotic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, arterial type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, Sack-Barabas type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ehlers-Danlos syndrome, type 4</ElementValue>
                <XRef ID="Ehlers-Danlos+Syndrome+Vascular+Type/2491" DB="Genetic Alliance" />
                <XRef ID="17025000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos Syndrome Type IV</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">EDS IV</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EDS4</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Vascular Ehlers-Danlos syndrome (vEDS) is characterized by arterial, intestinal, and/or uterine fragility; thin, translucent skin; easy bruising; characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes); and an aged appearance to the extremities, particularly the hands. Vascular dissection or rupture, gastrointestinal perforation, or organ rupture are the presenting signs in most adults with vEDS. Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection but also may occur spontaneously. The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history. Neonates may present with clubfoot, hip dislocation, limb deficiency, and/or amniotic bands. Approximately half of children tested for vEDS in the absence of a positive family history present with a major complication at an average age of 11 years. Four minor diagnostic features – distal joint hypermobility, easy bruising, thin skin, and clubfeet – are most often present in those children ascertained without a major complication.</Attribute>
                <XRef ID="NBK1494" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2082" />
                <XRef ID="2082" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301667</ID>
                <ID Source="BookShelf">NBK1494</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987428</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_Ehlers-DanlosTypeIV-enPro4042.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Type IV Ehlers-Danlos Syndrome</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="CCS, 2014">
                <ID Source="PubMed">24882528</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173340</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2017">
                <ID Source="PubMed">28161018</ID>
              </Citation>
              <XRef ID="286" DB="Orphanet" />
              <XRef ID="C0268338" DB="MedGen" />
              <XRef ID="MONDO:0017314" DB="MONDO" />
              <XRef Type="MIM" ID="130050" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3100499" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="11775978|MedGen:C0268338" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001574904" DateUpdated="2024-02-28" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24922459</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1066527). Disruption of this splice site has been observed in individual(s) with clinical features of Ehlers-Danlos syndrome (Invitae). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change affects a splice site in intron 13 of the COL3A1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in COL3A1 are known to be pathogenic (PMID: 24922459).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL3A1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.189856908del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268338" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3100499" TraitType="Disease" MappingType="XRef" MappingValue="C0268338" MappingRef="MedGen">
        <MedGen CUI="C0268338" Name="Ehlers-Danlos syndrome, type 4" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

